Trial Profile
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2022
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus First in man; Pharmacodynamics; Therapeutic Use
- Acronyms CEDAR
- 30 Jul 2021 Results presented at the Alzheimer's Association International Conference 2021
- 26 Oct 2020 Status changed from recruiting to completed.
- 28 Jun 2016 Status changed from not yet recruiting to recruiting.